SCHEMBL31023482

SCHEMBL31023482

COc1cc(Cl)ncc1C(=O)NCc1ccc(-c2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ PPARG P37231 1/20 0.54
▸ PPARA Q07869 1/20 0.54
▸ HPGD P15428 5/20 0.53
▸ TP53 P04637 1/20 0.53
▸ GLA P06280 1/20 0.53
▸ RAB9A P51151 2/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ ALDH1A1 P00352 3/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ PDE5A O76074 2/20 0.49
▸ LMNA P02545 3/20 0.49
▸ POLB P06746 1/20 0.49
▸ MAPK1 P28482 2/20 0.48
▸ HTT P42858 1/20 0.48
▸ RECQL P46063 1/20 0.48
▸ ROCK2 O75116 1/20 0.48
▸ ROCK1 Q13464 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023570 0.91 ROCK2 (0.54) SMN1; SMN2HPGDTP53GLARAB9A
SCHEMBL31023603 0.89 HPGDS (0.49) SMN1; SMN2PPARGPPARAHPGDTP53
SCHEMBL31023447 0.83 PPARA (0.58) PPARGPPARAPOLB
SCHEMBL31023473 0.82 HPGD (0.60) SMN1; SMN2PPARGPPARAHPGDTP53
SCHEMBL31023513 0.82 NR1H4 (0.54) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL31023598 0.81 PPARD (0.56) SMN1; SMN2PPARAHPGDALDH1A1POLB
SCHEMBL31023490 0.80 SMN1; SMN2 (0.61) SMN1; SMN2PPARGHPGDRAB9ANPC1
SCHEMBL31023560 0.79 EGLN1 (0.63) SMN1; SMN2PPARGPPARAHPGDTP53
SCHEMBL31023529 0.78 POLB (0.57) PPARAHPGDMEN1KMT2ALMNA
SCHEMBL31023605 0.78 ADORA3 (0.53) HPGDTP53RAB9AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027096-A1 PHD INHIBITORS UNIV OXFORD INNOVATION LTD (GB) 2026-01-29 — — US disclosed
EP-4655288-A1 PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 — — EP disclosed
EP-4655294-A1 PYRAZOLE DERIVSTIVES AS PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 — — EP disclosed
WO-2024157019-A1 PHD INHIBITORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-08-02 — — WO disclosed
WO-2024157014-A1 PYRAZOLE DERIVSTIVES AS PHD INHIBITORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027096-A1 PHD INHIBITORS HIF1AN, HIF1A, EGLN1 SMN1; SMN2 3613/4885PPARG 1920/4885PPARA 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback